Home » Topics » BioWorld Science

BioWorld Science
RSS

PearlRiverBio patents mutant EGFR/HER2 inhibitors

Sep. 10, 2021

HA-344 shows promise for treating cutaneous metastatic melanoma

Sep. 10, 2021

Novel virulence factor LasB inhibitors for the treatment of P. aeruginosa infections

Sep. 10, 2021

Discovery of novel antibiotic class of tethered macrocyclic peptides

Sep. 10, 2021

New PIKfyve inhibitors identified at AcuraStem

Sep. 10, 2021

Salk Institute, Sanford Burnham Prebys describe new ULK1 inhibitors

Sep. 10, 2021

StemSynergy Therapeutics patents N-myc proto-oncogene protein inhibitors

Sep. 10, 2021

Small-molecule OXS-7417 shows in vivo AML antitumoral effects

Sep. 10, 2021

AFYX Therapeutics presents preclinical data on anti-TNF antibody delivery through adhesive patch

Sep. 10, 2021

PAQ and Insilico Medicine collaborate to develop therapies through autophagy-dependent degradation

Sep. 9, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
In the clinic for April 21, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...